A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes

Cytotechnology

Volumn 62, Issue 1, 2010, Pages 61-71

  Huang, Jianfei ^a,b   Tan, Yang ^a   Tang, Qi ^a   Liu, Xinjian ^a   Guan, Xiaohong ^a   Feng, Zhenqing ^a   Zhu, Jin ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c Huadong Medical Institute of Biotechniques   (China)

Author keywords

Conformational epitope; Hybridoma technology; Linear epitope; Monoclonal antibody; Vascular endothelial growth factor receptor 2

Indexed keywords

A8H1 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CELL NUCLEUS; CELL STRAIN 3T3; CONTROLLED STUDY; CROSS REACTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOFLUORESCENCE TEST; INTRACELLULAR MEMBRANE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UMBILICAL VEIN;

EID: 77951879147     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-010-9262-4     Document Type: Article

References (25)

1. M Benedetta Donati J Gozdzikiewicz 2008 Angiogenesis and the progress of vascular and tumor biology: a tribute to Judah Folkman Thromb Haemost 99 647 650
2. P Benzinger G Martiny-Baron P Reusch G Siemeister JT Kley D Marmé C Unger U Massing 2000 Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro Biochim Biophys Acta 1466 71 78 10.1016/S0005-2736(00) 00172-3 1:CAS:528:DC%2BD3cXjsVGiur0%3D (Pubitemid 30312966)
3. T Böldicke H Weber PP Mueller B Barleon M Bernal 2005 New highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) J Immunol Methods 303 153 154 10.1016/j.jim.2005.08.003 (Pubitemid 41169956)
4. G Calogiuri MT Ventura L Mason A Valacca R Buquicchio N Cassano GA Vena 2008 Hypersensitivity reactions to last generation chimeric, humanized [correction of humanized] and human recombinant monoclonal antibodies for therapeutic use Curr Pharm Des 14 2883 2891 10.2174/138161208786369786 1:CAS:528:DC%2BD1cXhsVKgu7bE
5. P Chiarella VM Fazio 2008 LinksMouse monoclonal antibodies in biological research: strategies for high-throughput production Biotechnol Lett 30 1303 1310 10.1007/s10529-008-9706-5 1:CAS:528:DC%2BD1cXnsVCrtro%3D
6. PM Deckert 2009 Current constructs and targets in clinical development for antibody-based cancer therapy Curr Drug Targets 10 158 175 10.2174/138945009787354502 1:CAS:528:DC%2BD1MXks1Cgtro%3D
7. HF Dvorak 2002 Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 4368 4380 10.1200/JCO.2002.10.088 1:CAS:528:DC%2BD38Xpt1CjtL0%3D (Pubitemid 35266299)
8. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 795 803 10.1038/nrc909 1:CAS:528:DC%2BD38XnsVGrtbk%3D (Pubitemid 37328914)
9. N Ferrara 2005 The role of VEGF in the regulation of physiological and pathological angiogenesis EXS 94 209 231
10. H Gitay-Goren S Soker I Vlodavsky G Neufeld 1992 The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules J Biol Chem 267 6093 6098 1:CAS:528:DyaK38XitVymt7k%3D
11. A Kiselyov KV Balakin SE Tkachenko 2007 VEGF/VEGFR signalling as a target for inhibiting angiogenesis Expert Opin Investig Drugs 16 83 107 10.1517/13543784.16.1.83 1:CAS:528:DC%2BD28Xht1yisL7J (Pubitemid 44964169)
12. G Köhler C Milstein 1975 Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495 497 10.1038/256495a0
13. R Li DS Xiong XF Shao J Liu YF Xu YS Xu HZ Liu ZP Zhu CZ Yang 2004 Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II Acta Pharmacol Sin 25 1292 1298 1:CAS:528:DC%2BD2cXovVeqsb4%3D
14. K Nakamura Y Zen Y Sato K Kozaka O Matsui K Harada Y Nakanuma 2007 Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver Hum Pathol 38 1532 1546 10.1016/j.humpath.2007.03.002 1:CAS:528:DC%2BD2sXhtVOgu77L (Pubitemid 47418965)
15. K Paz Z Zhu 2005 Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective Front Biosci 10 1415 1439 10.2741/1629 1:CAS:528:DC%2BD2MXisVekurg%3D
16. M Popkov N Jendreyko G Gonzalez-Sapienza RG Mage C Rader CF Barbas 3rd 2004 Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library J Immunol Methods 288 149 164 10.1016/j.jim.2004.03.005 1:CAS:528:DC%2BD2cXks1WksLc%3D (Pubitemid 38739260)
17. P Roth C Hammer AC Piguet M Ledermann JF Dufour E Waelti 2007 Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2 J Drug Target 15 623 631 10.1080/10611860701502723 1:CAS:528:DC%2BD2sXht1ahtbvK (Pubitemid 350031086)
18. S Schenone F Bondavalli M Botta 2007 Antiangiogenic agents: an update on small molecule VEGFR inhibitors Curr Med Chem 14 2495 2516 10.2174/ 092986707782023622 1:CAS:528:DC%2BD2sXhtVKqtrbN (Pubitemid 47618038)
19. M Shibuya 2001 Structure and function of VEGF/VEGF-receptor system involved in angiogenesis Cell Struct Func 26 25 35 10.1247/csf.26.25 1:CAS:528:DC%2BD3MXjvVyjuro%3D (Pubitemid 32421949)
20. M Stewart H Turley N Cook F Pezzella G Pillai D Ogilvie S Cartlidge D Paterson C Copley J Kendrew C Barnes AL Harris KC Gatter 2003 The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study Histopathology 43 33 39 10.1046/j.1365-2559.2003.01644.x 1:STN:280:DC%2BD3szlt1Shtg%3D%3D (Pubitemid 36836585)
21. T Takahashi M Shibuya 1997 The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts Oncogene 14 2079 2089 10.1038/sj.onc.1201047 1:CAS:528:DyaK2sXjsVKhsrw%3D
22. H Wang K Chen G Niu X Chen 2009 Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis Mol Pharm 6 285 294 10.1021/mp800185h 1:CAS:528:DC%2BD1cXhsFantbvO
23. L Witte DJ Hicklin Z Zhu B Pytowski H Kotanides P Rockwell P Böhlen 1998 Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy Cancer Metastasis Rev 17 155 161 10.1023/A:1006094117427 1:CAS:528:DyaK1cXmtlymsLc%3D (Pubitemid 28391949)
24. Z Zhu D Lu H Kotanides A Santiago X Jimenez T Simcox DJ Hicklin P Bohlen L Witte 1999 Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody Cancer Lett 136 203 213 10.1016/S0304- 3835(98)00324-3 1:CAS:528:DyaK1MXhs1Oisbg%3D (Pubitemid 29164395)
25. Z Zhu K Hattori H Zhang X Jimenez DL Ludwig S Dias P Kussie H Koo HJ Kim D Lu M Liu R Tejada M Friedrich P Bohlen L Witte S Rafii 2003 Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity Leukemia 17 604 611 10.1038/sj.leu.2402831 1:CAS:528:DC%2BD3sXitFentbk%3D (Pubitemid 36395655)